文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

迎接挑战:掌握艰难梭菌感染的管理。

Rise to the Challenge: Master the Management of Clostridioides difficile Infection.

机构信息

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.

出版信息

Mayo Clin Proc. 2024 Jun;99(6):971-979. doi: 10.1016/j.mayocp.2024.02.022.


DOI:10.1016/j.mayocp.2024.02.022
PMID:38839189
Abstract

Clostridioides difficile infection (CDI) is a significant public health challenge in the developed world. Although previously CDI was primarily a health care-acquired infection, there are now rising numbers of community-acquired cases in patients without traditional risk factors, such as antibiotic exposure. The landscape for the treatment of CDI has changed significantly during the past decade, including newer diagnostic tests, novel antibiotic regimens, and strategies for microbiome restoration in the form of traditional fecal microbiota transplant and approved live biotherapeutics in an effort to address the underlying pathophysiologic process of gut microbial dysbiosis. We present a concise review for clinicians on the diagnosis and management of both primary and recurrent CDI.

摘要

艰难梭菌感染(CDI)是发达国家面临的重大公共卫生挑战。尽管以前 CDI 主要是医源性感染,但现在在没有传统危险因素(如抗生素暴露)的患者中,社区获得性病例的数量正在上升。在过去十年中,CDI 的治疗方法发生了重大变化,包括新的诊断测试、新型抗生素方案以及以传统粪便微生物移植和批准的活体生物治疗为形式的微生物组恢复策略,以解决肠道微生物失调的潜在病理生理过程。我们为临床医生提供了关于原发性和复发性 CDI 的诊断和管理的简明综述。

相似文献

[1]
Rise to the Challenge: Master the Management of Clostridioides difficile Infection.

Mayo Clin Proc. 2024-6

[2]
Current and future trends in clostridioides (clostridium) difficile infection management.

Anaerobe. 2019-5-1

[3]
Breaking the Cycle of Recurrent Infections: A Narrative Review Exploring Current and Novel Therapeutic Strategies.

J Pharm Pract. 2024-12

[4]
Diluted Fecal Community Transplant Restores Clostridioides difficile Colonization Resistance to Antibiotic-Perturbed Murine Communities.

mBio. 2022-8-30

[5]
Functional profile of host microbiome indicates infection.

Gut Microbes. 2022

[6]
Therapeutics for infection: molecules and microbes.

Expert Rev Gastroenterol Hepatol. 2023

[7]
Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention.

Clin Infect Dis. 2023-12-5

[8]
Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day!

J Intern Med. 2021-8

[9]
Fecal Microbiota Transplantation Increases Colonic IL-25 and Dampens Tissue Inflammation in Patients with Recurrent Clostridioides difficile.

mSphere. 2021-10-27

[10]
Navigating changes in prevention and treatment.

J Manag Care Spec Pharm. 2020-12

引用本文的文献

[1]
subsp. dipro-O: a potential therapeutic agent for ameliorating metabolic disorders in high-fat diet-induced obesity mouse model.

Front Endocrinol (Lausanne). 2025-6-6

[2]
Infection in the Elderly: Trend Analysis from 2000 to 2019.

J Clin Med. 2024-6-26

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索